CA3036694A1 - Treatment of multiple sclerosis with chs-131 - Google Patents
Treatment of multiple sclerosis with chs-131 Download PDFInfo
- Publication number
- CA3036694A1 CA3036694A1 CA3036694A CA3036694A CA3036694A1 CA 3036694 A1 CA3036694 A1 CA 3036694A1 CA 3036694 A CA3036694 A CA 3036694A CA 3036694 A CA3036694 A CA 3036694A CA 3036694 A1 CA3036694 A1 CA 3036694A1
- Authority
- CA
- Canada
- Prior art keywords
- effective amount
- therapeutically effective
- compound
- multiple sclerosis
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394046P | 2016-09-13 | 2016-09-13 | |
| US62/394,046 | 2016-09-13 | ||
| US201662436356P | 2016-12-19 | 2016-12-19 | |
| US62/436,356 | 2016-12-19 | ||
| US201762460868P | 2017-02-19 | 2017-02-19 | |
| US62/460,868 | 2017-02-19 | ||
| US201762491071P | 2017-04-27 | 2017-04-27 | |
| US62/491,071 | 2017-04-27 | ||
| PCT/US2017/051414 WO2018053040A1 (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with chs-131 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036694A1 true CA3036694A1 (en) | 2018-03-22 |
Family
ID=61619253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036694A Abandoned CA3036694A1 (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with chs-131 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190224186A1 (enExample) |
| EP (1) | EP3512512A4 (enExample) |
| JP (1) | JP2019531286A (enExample) |
| KR (1) | KR20190064583A (enExample) |
| CN (1) | CN110461318A (enExample) |
| AU (1) | AU2017326261A1 (enExample) |
| BR (1) | BR112019004791A2 (enExample) |
| CA (1) | CA3036694A1 (enExample) |
| IL (1) | IL265259A (enExample) |
| MX (1) | MX2019002901A (enExample) |
| SG (1) | SG10202102198RA (enExample) |
| WO (1) | WO2018053040A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| EA201992364A1 (ru) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EA201590726A1 (ru) * | 2012-10-12 | 2015-10-30 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для уменьшения таламического поражения при рассеянном склерозе |
| BR112015018048A2 (pt) * | 2013-01-30 | 2020-01-28 | Intekrin Therapeutics Inc | agonistas de ppary para tratamento de esclerose múltipla |
-
2017
- 2017-09-13 SG SG10202102198RA patent/SG10202102198RA/en unknown
- 2017-09-13 JP JP2019513922A patent/JP2019531286A/ja active Pending
- 2017-09-13 BR BR112019004791A patent/BR112019004791A2/pt not_active Application Discontinuation
- 2017-09-13 MX MX2019002901A patent/MX2019002901A/es unknown
- 2017-09-13 US US16/333,171 patent/US20190224186A1/en not_active Abandoned
- 2017-09-13 CA CA3036694A patent/CA3036694A1/en not_active Abandoned
- 2017-09-13 AU AU2017326261A patent/AU2017326261A1/en not_active Abandoned
- 2017-09-13 KR KR1020197009963A patent/KR20190064583A/ko not_active Ceased
- 2017-09-13 WO PCT/US2017/051414 patent/WO2018053040A1/en not_active Ceased
- 2017-09-13 CN CN201780069826.5A patent/CN110461318A/zh not_active Withdrawn
- 2017-09-13 EP EP17851479.0A patent/EP3512512A4/en not_active Withdrawn
-
2019
- 2019-03-10 IL IL265259A patent/IL265259A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110461318A (zh) | 2019-11-15 |
| IL265259A (en) | 2019-05-30 |
| EP3512512A1 (en) | 2019-07-24 |
| WO2018053040A1 (en) | 2018-03-22 |
| BR112019004791A2 (pt) | 2019-06-04 |
| EP3512512A4 (en) | 2020-06-03 |
| AU2017326261A1 (en) | 2019-04-04 |
| SG10202102198RA (en) | 2021-04-29 |
| JP2019531286A (ja) | 2019-10-31 |
| MX2019002901A (es) | 2019-09-26 |
| US20190224186A1 (en) | 2019-07-25 |
| KR20190064583A (ko) | 2019-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chapple et al. | A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | |
| JP4097285B2 (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
| CN116059204A (zh) | 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 | |
| Foote et al. | Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist | |
| CA3036694A1 (en) | Treatment of multiple sclerosis with chs-131 | |
| AU2014212740B2 (en) | PPARy agonists for treatment of multiple sclerosis | |
| JP2015522630A (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| KR20170068480A (ko) | 다발성 경화증의 치료를 위한 시포니모드 및 라퀴니모드를 포함하는 조합물 | |
| RU2563821C2 (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| RS64481B1 (sr) | Lečenje alchajmerove bolesti kod posebne populacije pacijenata | |
| CN119421710A (zh) | 偏头痛的预防治疗 | |
| KR100951540B1 (ko) | 탈수초성 질병 또는 상태 치료용 약제학적 조성물 | |
| EP2882495A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders | |
| US12318380B2 (en) | Treatment of demyelinating diseases | |
| KR20190061027A (ko) | 비-알코올성 지방간 질환의 치료를 위한 약학 조성물 및 방법 | |
| JP2023515429A (ja) | 多発性硬化症患者の亜集団の処置のためのマシチニブ | |
| Chung et al. | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients | |
| Nardulli et al. | Combined antimuscarinics for treatment of neurogenic overactive bladder | |
| US20040142968A1 (en) | Method and kit for treating lower bowel pain | |
| KR20250004041A (ko) | 삼차 신경통 치료 및 그와 관련된 통증 감소에 사용하기 위한 트리메프라진 | |
| JP7365696B2 (ja) | 鎮痛剤及び鎮静剤 | |
| CN115715191A (zh) | 排尿症状治疗剂 | |
| JP2022515615A (ja) | 慢性炎症性腸疾患の治療のためのｐａｒ－１アンタゴニストの使用 | |
| Alla et al. | Safety and efficacy of intermittent versus continuous anticholinergic medication in management of overactive bladder in adult | |
| RU2805061C2 (ru) | Лечение демиелинизирующих заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20231228 |